The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ALRN | -67.16% | -94.76% | -44.56% | -99% |
| S&P | +18.33% | +108.18% | +15.79% | +185% |
Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Waltham, MA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.00M | 75.0% |
| Market Cap | $31.02M | -48.1% |
| Market Cap / Employee | $2.82M | 0.0% |
| Employees | 11 | -26.7% |
| Net Income | -$6.82M | 23.7% |
| EBITDA | -$6.87M | 24.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $5.72M | -73.9% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -70.89% | -30.0% |
| Return On Invested Capital | -101.75% | 5.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$6.42M | 23.5% |
| Operating Free Cash Flow | -$6.42M | 23.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.37 | 0.99 | 0.76 | 6.32 | 506.31% |
| Price to Tangible Book Value | -2.59 | -1.41 | -1.09 | -0.71 | -38.31% |
| Enterprise Value to EBITDA | -17.13 | -14.14 | -13.62 | -10.65 | 22.99% |
| Return on Equity | -54.9% | -82.4% | -86.8% | -79.4% | 79.11% |
| Total Debt | $0.00M | $0.00M | $0.00M | $0.00M | - |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
